UK markets close in 6 hours 38 minutes
  • FTSE 100

    7,489.46
    +1.31 (+0.02%)
     
  • FTSE 250

    19,984.35
    +71.95 (+0.36%)
     
  • AIM

    913.18
    -1.57 (-0.17%)
     
  • GBP/EUR

    1.1836
    +0.0017 (+0.14%)
     
  • GBP/USD

    1.2098
    +0.0022 (+0.18%)
     
  • BTC-GBP

    19,076.13
    -694.30 (-3.51%)
     
  • CMC Crypto 200

    536.35
    -21.00 (-3.77%)
     
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • DOW

    32,774.41
    -58.13 (-0.18%)
     
  • CRUDE OIL

    90.34
    -0.16 (-0.18%)
     
  • GOLD FUTURES

    1,808.70
    -3.60 (-0.20%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    19,610.84
    -392.60 (-1.96%)
     
  • DAX

    13,562.33
    +27.36 (+0.20%)
     
  • CAC 40

    6,491.78
    +1.78 (+0.03%)
     

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·12-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2021:

  • Cash: € 761,542.29

  • Number of shares: 45,462

  • Number of executions on buy side on semester: 1,253

  • Number of executions on sell side on semester: 1,425

  • Traded volume on buy side on semester: 209,935 shares for € 2,438,368.87

  • Traded volume on sell side on semester: 211,076 shares for € 2,510,782.11

At the last half-year report as of June 30, 2021, the following resources were available in the liquidity account:

  • Cash: € 689,129.05

  • Number of shares: 46,603

  • Number of executions on buy side on semester: 1,511

  • Number of executions on sell side on semester: 1,435

  • Traded volume on buy side on semester: 289,008 shares for € 3,547,633.77

  • Traded volume on sell side on semester: 257,898 shares for € 3,208,144.47

When the contract was initially implemented, the following resources were included in the liquidity account:

  • Cash: € 163,510.42

  • Number of shares: 34,063

Buy Side

Sell Side

Number of
executions

Number of
shares

Traded volume in EUR

Number of
executions

Number of
shares

Traded volume in EUR

Total

1,253

209,935

2,438,368.87

1,425

211,076

2,510,782.11

01/07/2021

-

-

-

25

4,000

47,320.00

02/07/2021

-

-

-

11

1,500

18,105.00

05/07/2021

6

2,500

29,750.00

-

-

-

06/07/2021

-

-

-

18

3,310

40,150.30

07/07/2021

15

4,500

53,370.00

18

3,474

41,965.92

08/07/2021

34

4,500

52,920.00

1

1

12.02

09/07/2021

7

672

7,788.48

1

1

11.76

12/07/2021

16

1,432

16,625.52

5

503

5,885.10

13/07/2021

4

896

10,304.00

11

1,229

14,305.56

14/07/2021

-

-

-

8

886

10,410.50

15/07/2021

4

1,459

16,793.09

7

1,713

20,350.44

19/07/2021

2

500

5,930.00

2

168

2,009.28

20/07/2021

10

1,000

11,830.00

5

500

5,950.00

21/07/2021

-

-

-

8

1,500

17,925.00

22/07/2021

1

1

12.00

27

2,527

30,728.32

23/07/2021

17

1,501

18,237.15

3

506

6,203.56

26/07/2021

47

4,499

53,358.14

-

-

-

27/07/2021

11

1,156

13,432.72

13

1,280

15,065.60

28/07/2021

14

1,386

16,008.30

1

1

11.64

29/07/2021

18

2,265

25,843.65

4

1,669

19,410.47

30/07/2021

5

500

5,680.00

5

501

5,711.40

02/08/2021

4

1,000

11,380.00

8

1,225

14,099.75

03/08/2021

44

6,852

75,988.68

2

1,000

11,130.00

04/08/2021

32

4,500

48,870.00

-

-

-

05/08/2021

54

7,000

72,310.00

-

-

-

06/08/2021

26

6,000

58,620.00

-

-

-

09/08/2021

16

2,500

23,750.00

-

-

-

11/08/2021

9

1,500

14,340.00

-

-

-

12/08/2021

16

1,300

12,233.00

-

-

-

13/08/2021

3

500

4,585.00

-

-

-

16/08/2021

-

-

-

1

70

658.00

17/08/2021

-

-

-

4

500

4,750.00

19/08/2021

-

-

-

4

500

4,900.00

20/08/2021

9

1,300

12,402.00

-

-

-

23/08/2021

-

-

-

15

1,248

12,367.68

24/08/2021

-

-

-

7

1,229

12,314.58

25/08/2021

-

-

-

8

2,023

20,594.14

26/08/2021

-

-

-

1

500

5,100.00

27/08/2021

7

500

5,050.00

17

2,592

26,723.52

30/08/2021

-

-

-

13

1,908

20,110.32

31/08/2021

-

-

-

30

4,600

50,232.00

01/09/2021

6

1,500

16,365.00

12

2,748

30,805.08

02/09/2021

29

1,000

11,080.00

11

2,752

31,042.56

03/09/2021

2

340

3,842.00

1

19

216.60

06/09/2021

1

160

1,808.00

6

981

11,212.83

07/09/2021

4

577

6,572.03

2

774

8,916.48

08/09/2021

3

244

2,781.60

9

1,000

11,530.00

09/09/2021

-

-

-

26

3,551

41,866.29

10/09/2021

13

2,000

23,360.00

-

-

-

13/09/2021

52

8,179

91,604.80

-

-

-

14/09/2021

-

-

-

15

1,500

16,875.00

15/09/2021

2

401

4,515.26

4

2,000

22,860.00

16/09/2021

-

-

-

4

1,000

11,590.00

17/09/2021

-

-

-

21

2,684

31,590.68

20/09/2021

5

1,500

17,625.00

23

3,316

39,360.92

21/09/2021

5

1,000

11,830.00

10

1,000

11,930.00

22/09/2021

-

-

-

41

6,500

80,925.00

23/09/2021

4

1,500

18,465.00

9

1,000

12,480.00

24/09/2021

15

5,000

60,400.00

18

2,500

30,900.00

27/09/2021

17

2,001

24,072.03

22

3,001

36,462.15

28/09/2021

9

2,000

24,060.00

7

1,500

18,345.00

29/09/2021

15

3,001

35,471.82

5

373

4,423.78

30/09/2021

4

499

5,818.34

11

3,127

37,430.19

01/10/2021

26

4,805

55,930.20

7

820

9,635.00

04/10/2021

4

1,500

17,265.00

5

510

5,946.60

05/10/2021

5

695

7,950.80

13

1,000

11,580.00

06/10/2021

13

2,501

28,411.36

9

500

5,780.00

07/10/2021

17

3,399

37,796.88

4

1,000

11,180.00

08/10/2021

16

3,100

33,728.00

9

2,000

22,060.00

11/10/2021

1

1

10.80

42

4,000

44,320.00

12/10/2021

-

-

-

52

6,576

75,689.76

13/10/2021

1

500

5,800.00

5

500

5,850.00

14/10/2021

6

1,500

17,415.00

2

500

5,880.00

15/10/2021

5

1,000

11,580.00

2

119

1,392.30

18/10/2021

10

2,000

22,920.00

9

500

5,800.00

19/10/2021

-

-

-

42

6,475

77,635.25

20/10/2021

13

1,626

19,430.70

3

1,000

12,340.00

21/10/2021

1

500

6,010.00

17

2,500

30,650.00

22/10/2021

6

1,001

12,242.23

14

1,500

18,615.00

25/10/2021

14

3,429

41,765.22

13

2,771

34,138.72

26/10/2021

6

2,000

24,940.00

46

6,729

84,650.82

27/10/2021

27

5,001

62,512.50

5

1,174

14,921.54

28/10/2021

3

1,001

12,442.43

12

2,406

30,219.36

29/10/2021

1

498

6,155.28

22

3,920

49,901.60

01/11/2021

5

501

6,412.80

7

1,000

12,980.00

02/11/2021

4

1,000

12,780.00

3

1,500

19,425.00

03/11/2021

21

3,823

48,513.87

-

-

-

04/11/2021

13

4,176

52,534.08

49

5,741

73,255.16

05/11/2021

26

5,570

68,789.50

-

-

-

08/11/2021

7

1,891

22,559.63

-

-

-

09/11/2021

5

1,483

17,499.40

56

6,222

76,095.06

10/11/2021

15

2,000

24,260.00

1

136

1,672.80

11/11/2021

25

4,600

57,224.00

53

4,957

62,160.78

12/11/2021

23

3,400

41,140.00

1

1

12.46

15/11/2021

19

2,500

29,650.00

3

1,000

11,880.00

16/11/2021

30

2,611

30,679.25

21

1,000

11,980.00

17/11/2021

9

1,489

17,227.73

2

500

5,850.00

18/11/2021

8

900

10,332.00

2

1,000

11,630.00

19/11/2021

30

2,774

31,817.78

8

2,613

30,336.93

22/11/2021

-

-

-

15

2,946

34,409.28

23/11/2021

1

20

233.20

23

2,996

35,742.28

24/11/2021

17

3,519

40,996.35

14

1,506

17,680.44

25/11/2021

1

6

70.20

30

3,958

47,218.94

26/11/2021

12

2,995

35,191.25

11

2,000

23,660.00

29/11/2021

-

-

-

21

2,643

31,478.13

30/11/2021

21

4,499

52,773.27

7

1,000

11,760.00

01/12/2021

-

-

-

29

3,857

46,014.01

02/12/2021

9

1,938

23,081.58

3

1,183

14,172.34

03/12/2021

7

2,562

30,308.46

7

1,183

14,172.34

06/12/2021

-

-

-

22

4,615

55,564.60

07/12/2021

3

500

6,030.00

13

2,000

24,480.00

08/12/2021

-

-

-

23

3,500

43,890.00

09/12/2021

9

3,000

36,240.00

13

1,500

18,225.00

10/12/2021

11

2,500

30,000.00

2

501

6,092.16

13/12/2021

13

1,500

17,715.00

13

2,000

23,860.00

14/12/2021

-

-

-

13

1,999

24,247.87

15/12/2021

16

2,000

24,040.00

-

-

-

16/12/2021

8

2,000

24,240.00

19

3,033

36,941.94

17/12/2021

2

500

6,030.00

2

468

5,709.60

20/12/2021

30

3,501

41,486.85

-

-

-

21/12/2021

5

1,499

17,403.39

7

1,099

12,847.31

22/12/2021

3

16

185.60

15

3,453

41,125.23

23/12/2021

10

1,484

17,644.76

7

2,454

29,619.78

24/12/2021

1

1

12.06

7

686

8,382.92

27/12/2021

12

2,999

36,437.85

15

1,807

22,298.38

28/12/2021

18

3,000

35,940.00

8

1,000

12,180.00

29/12/2021

8

2,000

23,620.00

5

1,518

18,140.10

30/12/2021

-

-

-

2

11

130.90

31/12/2021

4

500

5,880.00

-

-

-

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases resulting in the discovery of the drug candidate cedirogant (AABV-157), an oral RORg inverse agonist. Cedirogant has reached clinical proof of concept during a Phase Ib clinical trial and is currently being evaluated in a Phase IIb clinical trial in patients with moderate to severe chronic plaque psoriasis. This collaboration enables Inventiva to receive payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from this collaboration.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients in 2019 and received both FDA Fast Track and Rare Paediatric Disease designation for odiparcil in MPS VI.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs

media@inventivapharma.com
+1 240 620 9175

Brunswick Group
Laurence Frost /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank

Investor relations
patti.bank@westwicke.com
+1 415 513 1284

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans, milestone and royalty payments and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, with respect to the anticipated timeline for seeking of regulatory approvals for candidates, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 202, Amendment No. 1 to our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 24, 2021, as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting